A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure

Experimental Eye Research

Volumn 132, Issue , 2015, Pages 115-123

  Nagai, Noriaki ^a   Yoshioka, Chiaki ^a   Mano, Yu ^a   Tnabe, Wataru ^a   Ito, Yoshimasa ^a   Okamoto, Norio ^b   Shimomura, Yoshikazu ^b  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Disulfiram; Drug delivery system; Eye drops; Glaucoma; Nanoparticle

Indexed keywords

DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; NANOPARTICLE; TIMOLOL MALEATE; EYE DROPS; SCAVENGER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORNEA; CORNEA EPITHELIUM; CORNEA PERMEABILITY; CORNEAL RESIDENCE TIME; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; INTRAOCULAR PRESSURE; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RABBIT; VISUAL SYSTEM PARAMETERS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; PATHOPHYSIOLOGY; PROCEDURES; WOUND HEALING;

ANIMALS; CORNEA; DISEASE MODELS, ANIMAL; DISULFIRAM; DRUG DELIVERY SYSTEMS; ESCHERICHIA COLI; FREE RADICAL SCAVENGERS; HUMANS; INTRAOCULAR PRESSURE; MALE; NANOPARTICLES; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; RABBITS; TONOMETRY, OCULAR; WOUND HEALING;

EID: 84922612491     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2015.01.022     Document Type: Article

References (55)

1. Abramoff M.D., Magelhaes P.J., Ram S.J. Image processing with image J. Biophot. Int. 2004, 11:36-42.
2. Araki-Sasaki K., Ohashi Y., Sasabe T., Hayashi K., Watanabe H., Tano Y., Handa H. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest. Ophthalmol. Vis. Sci. 1995, 36:614-621.
3. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 2007, 59:748-758.
4. Bacher W., Bade K., Matthis B. Fabrication of LIGA mold inserts. Microsyst. Technol. 1998, 4:117-119.
5. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 2004, 104:29-45.
6. Bender M., Otto M., Hadam B. Fabrication of nanostructures using a UV based imprint technique. Microelectron. Eng. 2000, 53:233-236.
7. Caldorera-Moore M., Guimard N., Shi L., Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin. Drug Deliv. 2010, 7:479-495.
8. Cohen S., Yoshioka T., Lucarelli M., Hwang L.H., Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 1991, 8:713-720.
9. Chouly C., Pouliquen D., Lucet I., Jeune J.J., Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J.Microencapsul. 1996, 13:245-255.
10. Dasgupta S., Ghosh S.K., Ray S., Mazumder B. Solid lipid nanoparticles (SLNs) gels for topical delivery of Aceclofenac invitro and invivo evaluation. Curr. Drug Deliv. 2013, 10:656-666.
11. Desai T.A., Hansford D.J., Kulinsky L., Nashat A.H., Rasi G., Tu J., Wang Y., Zhang M., Ferrari M. Nanopore technology for biomedical applications. J.Biomed. Microdev. 1999, 2:11-40.
12. Diebold Y., Calonge M. Applications of nanoparticles in ophthalmology. Prog. Retin. Eye Res. 2010, 29:596-609.
13. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 2008, 5:487-495.
14. Fang C., Shi B., Pei Y.Y., Hong M.H., Wu J., Chen H.Z. Invivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci. 2006, 27:27-36.
15. Goh Y., Hotehama Y., Mishima H.K. Characterization of ciliary muscle relaxation induced by various agents in cats. Invest. Ophthalmol. Vis. Sci. 1995, 36:1188-1192.
16. Guo L., Moss S.E., Alexander R.A., Ali R.R., Fitzke F.W., Cordeiro M.F. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest. Ophthalmol. Vis. Sci. 2005, 46:175-182.
17. Gupta H., Aqil M., Khar R.K., Ali A., Bhatnagar A., Mittal G. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J.Drug Target 2011, 19:409-417.
18. Gupta D., Tator C.H., Shoichet M.S. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomaterials 2006, 27:2370-2379.
19. Ito Y., Cai H., Koizumi Y., Nakao M., Terao M. Correlation between prevention of cataract development by disulfiram and fates of selenium in selenite-treated rats. Curr. Eye Res. 1999, 18:292-299.
20. Ito Y., Nagai N., Shimomura Y. Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-β-cyclodextrin in rabbit. Biol. Pharm. Bull. 2010, 33:1574-1578.
21. Kanai K., Ito Y., Nagai N., Itoh N., Hori Y., Chikazawa S., Hoshi F., Higuchi S. Effects of instillation of eyedrops containing disulfiram and hydroxypropyl-β-cyclodextrin inclusion complex on endotoxin-induced uveitis in rats. Curr. Eye Res. 2010, 37:124-131.
22. Kiel J.W., Reitsamer H.A., Walker J.S., Kiel F.W. Effects of nitric oxide synthase inhibition on ciliary blood flow, aqueous production and intraocular pressure. Exp. Eye Res. 2001, 73:355-364.
23. King G., Holmes R. Human ocular aldehyde dehydrogenase isozymes: distribution and properties as major soluble proteins in cornea and lens. J.Exp. Zool. 1998, 282:12-17.
24. Kundu P.P., Kundu M. Effect of salts and surfactant and their doses on the gelation of extremely dilute solutions of methyl cellulose. Polymer 2001, 42:2015-2020.
25. Li X., Zhang Z., Li J., Sun S., Weng Y., Chen H. Diclofenac/biodegradable polymer micelles for ocular applications. Nanoscale 2012, 4:4667-4673.
26. Lin C.P., Boehnke M. Influences of methylcellulose on corneal epithelial wound healing. J.Ocul. Pharmacol. Ther. 1999, 15:59-63.
27. Lin Y., Sun J., Jiang G., Zan J., Ding F. Invitro evaluation of lysozyme-loaded microspheres in thermosensitive methylcellulose- based hydrogel. Chin. J. Chem. Eng. 2007, 15:566-572.
28. Matthew C., Annette G., Byung Jin C. Patterning nonflat substrates with a low pressure, room temperature, imprint lithography process. J.Vac. Sci. Technol. B 2001, 19:2162-2172.
29. Mueller W.H., Deardorff D.L. Ophthalmic vehicles: the effect of methylcellulose on the penetration of homatropine hydrobromide through the cornea. J.Am. Pharm. Assoc. 1956, 45:334-341.
30. Nabekura T., Koizumi Y., Nakao M., Tomohiro M., Inomata M., Ito Y. Delay of cataract development in hereditary cataract UPL rats by disulfiram and aminoguanidine. Exp. Eye Res. 2003, 76:169-174.
31. Nagai N., Inomata M., Ito Y. Contribution of aldehyde dehydrogenase 3A1 to disulfiram penetration through monolayers consisting of cultured human corneal epithelial cells. Biol. Pharm. Bull. 2008, 31:1444-1448.
32. Nagai N., Ito Y. Adverse effects of excessive nitric oxide on cytochrome c oxidase in lenses of hereditary cataract UPL rats. Toxicology 2007, 242:7-15.
33. Nagai N., Ito Y. Anew preparation method for ophthalmic drug nanoparticles. Pharm. Anal. Acta 2014, 5(6):1000305. (an open access journal).
34. Nagai N., Ito Y. Effect of solid nanoparticle of indomethacin on therapy for rheumatoid arthritis in adjuvant-induced arthritis rat. Biol. Pharm. Bull. 2014, 37:1109-1118.
35. Nagai N., Ito Y. Therapeutic effects of gel ointments containing tranilast nanoparticles on paw edema in adjuvant-induced arthritis rats. Biol. Pharm. Bull. 2014, 37:96-104.
36. Nagai N., Ito Y. Excessive hydrogen peroxide enhances the attachment of amyloid β1-42 in the lens epithelium of UPL rats, a hereditary model for cataracts. Toxicology 2014, 315:55-64.
37. Nagai N., Ito Y., Okamoto N., Shimomura Y. Ananoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Toxicology 2014, 319:53-62.
38. Nagai N., Ito Y., Takeuchi N. Effect of disulfiram eye drops on lipid peroxide formation via excessive nitric oxide in lenses of hereditary cataract ICR/f rats. Biol. Pharm. Bull. 2008, 31:981-985.
39. Nagai N., Ito Y., Takeuchi N. Inhibitive effects of enhanced lipid peroxidation on Ca(2+)-ATPase in lenses of hereditary cataract ICR/f rats. Toxicology 2008, 247:139-144.
40. Nagai N., Ito Y., Takeuchi N. Pharmacokinetic and pharmacodynamic evaluation of the anti-cataract effect of eye drops containing disulfiram and low-substituted methylcellulose using ICR/f rats as a hereditary cataract model. Biol. Pharm. Bull. 2012, 35:239-245.
41. Nagai N., Ono H., Hashino M., Ito Y., Okamoto N., Shimomura Y. Improved corneal toxicity and permeability of tranilast by the preparation of ophthalmic formulations containing its nanoparticles. J.Oleo Sci. 2014, 63:177-186.
42. Nagai N., Takeda M., Ito Y., Takeuchi N., Kamei A. Delay in ICR/f rat lens opacification by the instillation of eye drops containing disulfiram and hydroxypropyl-beta-cyclodextrin inclusion complex. Biol. Pharm. Bull. 2007, 30:1529-1534.
43. Nagai N., Yoshioka C., Mano Y., Ito Y. Effect of eye drops containing disulfiram and low-substituted methylcellulose in reducing intraocular pressure in rabbit models. Curr. Eye Res. 2014, 20:1-11.
44. Probst C.E., Zrazhevskiy P., Bagalkot V., Gao X. Quantum dots as a platform for nanoparticle drug delivery vehicle design. Adv. Drug Deliv. Rev. 2013, 65:703-718.
45. Quigley H.A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 1996, 80:389-393.
46. Rafie F., Javadzadeh Y., Javadzadeh A.R., Ghavidel L.A., Jafari B., Moogooee M., Davaran S. Invivo evaluation of novel nanoparticles containing dexa-methasone for ocular drug delivery on rabbit eye. Curr. Eye Res. 2010, 35:1081-1089.
47. Resnick D.J., Sreenivasan S.V., Wilson C.G. Step and flash imprint lithography. Mater. Today 2005, 34-42.
48. Sanz T., Fernandez M.A., Salvador A., Munoz J., Fiszman S.M. Thermogelation properties of methylcellulose (MC) and their effect on a batter formula. Food Hydrocoll. 2005, 19:141-147.
49. Tate M.C., Shear D.A., Hoffman S.W., Stein D.G., LaPlaca M.C. Biocompatibility of methylcellulose-based constructs designed for intracerebral gelation following experimental traumatic brain injury. Biomaterials 2001, 22:1113-1123.
50. Tomoda K., Terashima H., Suzuki K., Inagi T., Terada H., Makino K. Enhanced transdermal delivery of indomethacin-loaded PLGA nanoparticles by iontophoresis. Colloids Surf. B. Biointerfaces 2011, 88:706-710.
51. Tomoda K., Terashima H., Suzuki K., Inagi T., Terada H., Makino K. Enhanced transdermal delivery of indomethacin using combination of PLGA nanoparticles and iontophoresis invivo. Colloids Surf. B. Biointerfaces 2012, 92:50-54.
52. Toy R., Peiris P.M., Ghaghada K.B., Karathanasis E. Shaping cancer nanomedicine: the effect of particle shape on the invivo journey of nanoparticles. Nanomedicine (Lond) 2014, 9:121-134.
53. Wells M.R., Kraus K., Batter D.K., Blunt D.G., Weremowitz J., Lynch S.E., Antoniades H.N., Hansson H.A. Gel matrix vehicles for growth factor application in nerve gap injuries repaired with tubes: a comparison of biomatrix, collagen, and methylcellulose. Exp. Neurol. 1997, 146:395-402.
54. Wiederholt M., Sturm A., Lepple W.A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest. Ophthalmol. Vis. Sci. 1994, 35:2515-2520.
55. Yakuji Nippo Ltd Japanese Pharmacopoeia 2011, Tokyo Maruzen Co., Ltd, 16.